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Abstract
Background: Glypican 3 (GPC-3) is an oncofoetal protein that is expressed in most hepatocellular carcinomas (HCC). 
Since it is a potential target for T cell immunotherapy, we investigated the generation of functional, GPC-3 specific T 
cells from peripheral blood mononuclear cells (PBMC).
Methods: Dendritic cells (DC) were derived from adherent PBMC cultured at 37°C for 7 days in X-Vivo, 1% autologous 
plasma, and 800 u/ml GM-CSF plus 500 u/ml IL-4. Immature DC were transfected with 20 μg of in vitro synthesised GPC-
3 mRNA by electroporation using the Easy-ject plus system (Equibio, UK) (300 V, 150 μF and 4 ms pulse time), or pulsed 
with peptide, and subsequently matured with lipopolysaccharide (LPS). Six predicted GPC-3 peptide epitopes were 
synthesized using standard f-moc technology and tested for their binding affinity to HLA-A2.1 molecules using the cell 
line T2.
Results: DC transfected with GPC-3 mRNA but not control DC demonstrated strong intracellular staining for GPC-3 and 
in vitro generated interferon-gamma expressing T cells from autologous PBMC harvested from normal subjects. One 
peptide, GPC-3522-530 FLAELAYDL, fulfilled our criteria as a naturally processed, HLA-A2-restricted cytotoxic T 
lymphocyte (CTL) epitope: i) it showed high affinity binding to HLA-A2, in T2 cell binding assay; ii) it was generated by 
the MHC class I processing pathway in DC transfected with GPC-3 mRNA, and iii) HLA-A2 positive DC loaded with the 
peptide stimulated proliferation in autologous T cells and generated CTL that lysed HLA-A2 and GPC-3 positive target 
cells.
Conclusions: These findings demonstrate that electroporation of GPC-3 mRNA is an efficient method to load human 
monocyte-derived DC with antigen because in vitro they generated GPC-3-reactive T cells that were functional, as 
shown by interferon-gamma production. Furthermore, this study identified a novel naturally processed, HLA-A2-
restricted CTL epitope, GPC-3522-530 FLAELAYDL, which can be used to monitor HLA-A2-restricted CTL responses in 
patients with HCC. Further studies are required to investigate whether anti-GPC-3 immunotherapy has a role in the 
treatment of GPC-3 dependent tumours, such as HCC.
Background
Increasing evidence suggests that immune responses play
an important role in the control of cancer and manipula-
tion of the immune system to recognize and attack cancer
cells may be a valuable form of therapy [1]. Hepatocellu-
lar carcinoma (HCC), which is the third most common
cause of cancer death world-wide [2], is a potential target
for immunotherapy [3] because there are numerous doc-
umented cases of spontaneous regression [4] and the
presence of cytotoxic tumour infiltrating lymphocytes
(TIL) at histological examination is associated with a bet-
ter prognosis after liver resection or transplantation [5].
Infusion of T lymphocytes, activated with anti CD3 and
interleukin 2 (IL2), improved disease-free survival after
HCC resection, suggesting a role for T cell immunother-
apy in this setting [6]. However, current methods of isola-
tion and in vitro expansion of T lymphocytes are
cumbersome and expensive, and the durability of any
anti-tumour immune response induced by administra-
tion of non-antigen specific, in vitro expanded T cells is
unknown [7].
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Many tumours, including HCC, express tumour-associ-
ated antigens (TAA) that might serve as potential targets
for antigen-specific T cell immunotherapy. Glypican 3
(GPC-3), a 580 amino acid glycosylphosphatidylinositol-
linked heparan sulphate proteoglycan, is expressed in
foetal liver and plays an important role in foetal develop-
ment because it facilitates the interaction of growth fac-
tors with their cognizant receptors [8]. It is rarely
detected in adult liver but is reactivated in 72% of HCC
[9], where its expression is correlated with a poor progno-
sis [10]. Intradermal vaccination of BALB/c mice with a
GPC-3 peptide (EYILSLEEL), restricted to the murine
MHC-I molecule H-2Kd, mixed with incomplete Freund's
adjuvant induced epitope specific, cytotoxic T lympho-
cytes (CTL) [11] and immunization using dendritic cells
(DC) pulsed with this peptide prevented the growth of
GPC-3 positive tumours [12]. Mice vaccinated with DC
expressing GPC-3 as a transgene were also found to have
protective immunity against subsequent challenge with
GPC-3 positive melanoma cells [13]. In a study of 20
HCC patients treated with locoregional therapy, 16 (80%)
were found to have TAA-specific CD8+ T cells, including
T cells directed against GPC-3 [14]. Furthermore, the
magnitude of the TAA-specific CD8+ T-cell response
was a significant independent prognostic factor for
tumour-free survival. These data suggest that GPC-3 is a
novel HCC-associated antigen but further studies are
required to investigate the immunogenicity of human
GPC-3 and to establish any therapeutic potential.
In this study, we demonstrate that human monocyte-
derived DC expressing GPC-3 antigen are able to induce,
in vitro, GPC-3-reactive T cells that are functional, as
shown interferon-gamma production. We also describe a
novel naturally processed, immunogenic epitope, GPC-
3522-530 FLAELAYDL, which is restricted to HLA-A2, a
common class 1 allele in various ethnic groups, including
Asians and Caucasians.
Methods
Cell lines
T2 cells (HLA-A*0201) and the human hepatocellular
carcinoma cell line HepG2 (HLA-A*0201 and GPC-3 pos-
itive) were obtained from ATCC and expression of HLA-
A2 and GPC-3 confirmed in the latter using flow cytome-
try, after staining with monoclonal antibodies against
HLA-A2.1 (BB7.2, Dako, UK), and GPC-3 (Biomosaics
Inc, Burlington, USA), respectively (data not shown). The
cell lines were cultured in RPMI (Gibco, UK) or DMEM
(Cambrex, UK), respectively, supplemented with 10% foe-
tal calf serum (FCS) (Cambrex, UK) and antibiotics (pen-
icillin G 100 IU/ml and Streptomycin 50 μg/ml).
T2 binding assays
The prediction tools SYFPEITHI [15] and HLAmotif [16]
were used to reveal GPC-3 peptide epitopes with pre-
dicted strong binding to HLA-A2. The top 30 peptides
were reassessed using RankPep [17], which also predicts
epitopes generated by the proteasome, and 6 peptide
epitopes were selected (Table 1). These peptides were
synthesized using standard f-moc technology (>95%
purity, as determined by reverse phase HPLC; Sigma,
UK), along with an AFP-derived, HLA-A2-binding pep-
tide (GVALQTMKQ) [18], and a random, non-HLA-A2
binding, control peptide (RGYVYQGL). The AFP peptide
has only one anchor but is an "immunodominant" epitope
[19] and its use was convenient because T cells reactive to
this epitope have been shown to lyse HepG2 cells. Due to
the hydrophobicity of peptides binding to HLA-A2, the
lyophilized peptides were resuspended in DMSO at 10
mM.
The selected epitopes were tested for their binding
affinity to HLA-A2.1 molecules using the cell line T2,
which is deficient in TAP1 and TAP 2 (transporters asso-
ciated with antigen processing 1 and 2) [20]. Although T2
cells express very low levels of HLA-A2.1 molecules
under normal culture conditions, cell surface expression
Table 1: GPC-3 peptides predicted to bind to HLA-A2 and be processed by the proteasome, and control peptides used in 
the study
GPC-3 peptide Position Sequence
1 229-237 FLQALNLGI
2 522-530 FLAELAYDL
3 299-307 YILSLEELV
4 186-194 GLPSALDI
5 222-230 SLQVTRIFL
6 169-177 ELFDSLFPV
AFP peptide GVALQTMKQ
Control peptide RGYVYQGLO'Beirne et al. Journal of Experimental & Clinical Cancer Research 2010, 29:48
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is upregulated when appropriate peptides bind and stabi-
lize the HLA-A2.1 molecule. Thus, up-regulation of
HLA-A2.1 expression in T2 cells by a peptide is regarded
as an indication of it being an HLA-A2.1-restricted
epitope [19]. HLA-A2.1 expression on the T2 cell surface
was quantified by staining the cells with HLA-A2-specific
antibody (1 μg/ml), as described [21]. To assess the stabil-
ity of the HLA-A2-peptide complex, 1 × 105 T2 cells were
incubated for 3 hours at 37°C with various concentrations
of peptide, 5 nM β2 microglobulin and 5 μg/ml Brefeldin
A, which inhibits the transportation of protein through
the Golgi and hence blocks delivery of new MHC class I
molecules to the cell surface. Cells were washed at the
end of each time point and stained for cell surface HLA-
A2 expression and then analyzed by flow cytometry.
Construction of RNA expression vector and in vitro 
transcription of mRNA
An RNA expression vector was constructed on the back-
bone of the PGEM 5Z(+) vector (Promega, Southampton,
UK). A 76 nucleotide poly-A sequence was cloned into
the vector between the Sph1 and Apa1 sites and a
sequence containing a new multiple cloning cassette and
the 3' untranslated region of the human α-globin gene, to
increase the intracellular stability of mRNA transcripts
[22], was inserted between the Sac1 and Sph1 sites. Sub-
sequently, the cDNA sequences encoding the open read-
ing frames of either GPC-3 or enhanced green
fluorescent protein (eGFP) were inserted between Nhe1
and Age1 sites in the new cloning cassette, downstream
of the SP6 promoter site of PGEM5Z and upstream of the
mRNA stabilizing sequences (Figure 1a). The 1.74 kb
GPC-3 open reading frame sequence was generated by
PCR from reverse transcribed RNA extracted from
HepG2 cells using primers 5'-CGAGCTAGCATGGGC-
CGGGACCGTG and 5'-AGGACCGGTGTGCACCAG-
GAAGAAGAAGC, which incorporated restriction sites
for Nhe1 and Age1, respectively. The vector was
sequenced to confirm authenticity.
The vector was linearized using a SnaB1 restriction site,
which is immediately downstream of the poly A
sequence, and the resulting linear DNA was isolated by
gel extraction. Following the manufacturers instructions,
the linear DNA (1 μg) served as template in an SP6
mMessage Machine reaction (Ambion, Huntingdon, UK).
After 3 hours at 37°C the capped mRNA was extracted
and purified using RNAeasy columns (Qiagen, Crawley,
UK). Transcripts were then analyzed and quantified by
denaturing agarose gel electrophoresis before use.
Dendritic cell culture and mRNA transfection
Fresh heparinised, peripheral blood samples were
obtained from HLA-A2 positive, normal subjects,
according to a protocol approved by The Kings College
Hospital Ethical Committee (LREC Protocol number 01/
248). Informed, written consent was obtained and the
study was performed according to the principles of World
Medical Association Declaration of Helsinki. DC were
derived from PBMC essentially as described by Romani
et al [23]. Adherent cells (7 × 106 per well of 6-well plates;
Nunc, UK) were cultured at 37°C for 7 days in X-Vivo, 1%
autologous plasma, and 800 u/ml GM-CSF plus 500 u/ml
interleukin-4 (IL-4) (both from R&D Systems, Abingdon,
UK) with cytokine replenishment after 3 days.
Immature DC were transfected with mRNA by elec-
troporation in 400 μL of X-Vivo with no supplements in a
4 mm cuvette using the Easy-ject plus system (Equibio,
Ashford, UK) at 300 V and 150 μF and a pulse time of 4
ms. After electroporation, DC were resuspended in 3 ml
of X-Vivo with antibiotics and rested for 1 hour.
ELISPOT and T cell proliferation assays
PBMC were depleted of HLA class II positive cells, using
anti-HLA Class II-coated magnetic particles (Dynabeads,
Dynal Biotech, Wirral, UK). ELISPOT assay (U-Cytech,
Netherlands) was performed to determine the number of
cells producing interferon-gamma. Briefly, HLA class II-
depleted cells were seeded in 96 well plates (1 × 105/well)
and co-cultured with autologous, γ-irradiated (4,000
rads), matured DC (1 × 104/well) in serum-free X-V ivo
medium supplemented on days 1, 3 and 7 of culture with
IL-2 (20 U/ml) and IL-7 (10 ng/ml) (both from R&D sys-
tems, UK). Cells were re-stimulated after 7 days with
autologous, γ-irradiated, matured DC (1 × 104/well) in
the presence of IL-2 and IL-7 and 24 hours after the sec-
ond stimulation with antigen-loaded DC, T cells were
washed and plated at 1 × 105 cells/well of the ELISPOT
plates, which were incubated for 5 hours before being
washed and developed. T cells supplemented with PHA
(10 μg/ml) acted as a positive control.
To assess T cell proliferation, HLA class II-depleted
cells were seeded in 96 well plates (1 × 105/well) and co-
cultured with autologous, γ-irradiated (4,000 rads),
matured DC (1 × 104/well) in serum-free X-Vivo medium
supplemented on days 1, 3 and 7 of culture with IL-2 (20
U/ml) and IL-7 (10 ng/ml) (both from R&D systems, UK).
Cells were re-stimulated after 7 days with autologous, γ-
irradiated, matured DC (1 × 104/well) in the presence of
IL-2 and IL-7 and cultures incubated for a further 5 days;
3H-thymidine (Amersham Pharmacia Biotech, Amer-
sham, Bucks, UK) was added for the last 18 hours of cul-
ture. DC were either transfected with mRNA or pulsed
with 1 μM peptides for 3 hours, and matured with LPS
(100 ng/ml) (Sigma, UK) for 16 hours.
Chromium release assay
A chromium release assay was used to assess the ability of
CTL to lyse target cells. Briefly, PBMC were enriched forO'Beirne et al. Journal of Experimental & Clinical Cancer Research 2010, 29:48
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CD8+ cells by depletion of CD4+ cells using anti-CD4
microbeads (MACS beads, Miltenyi Biotec, Bergisch
Gladbach, Germany) and these cells (1 × 106 cells/well)
were co-cultured with autologous, γ-irradiated (4,000
rads) DC (1 × 105 cells/well in 6 well plates), which had
been pulsed with 1 μM peptides for 3 hours and matured
with LPS (100 ng/ml) for 16 hours. Cells were cultured in
serum-free X-Vivo medium supplemented on days 1, 3
and 7 with IL-2 (20 U/ml) and IL-7 (10 ng/ml) (both from
R&D systems, UK). Cells were re-stimulated after 7 days
with peptide-pulsed DC and, 5 days after the second
stimulation, the cytotoxic activity of the expanded T cells
was measured by chromium release assay. Target cells
(HepG2) were labelled with 200 μCi Na2
51CrO4 (Amer-
sham, UK) in 0.5 ml DMEM containing 10% FCS for 60
minutes at 37°C. The cells were washed 3 times with
warm medium and plated at 5 × 103 cells/well in round-
bottomed 96 well plates (Nunc). Effector cells were added
at graded effector/target ratios in a final volume of 200 μl/
well. After 4 hours incubation at 37°C, 50 μl of the culture
supernatant was harvested and radioactivity counted in a
scintillation counter (Beckmann, USA). For controls,
maximum chromium release was achieved by the addi-
tion of 10% Triton-X and spontaneous release was
Figure 1 Expression of transgenes in monocyte-derived dendritic cells following transfection by electroporation of mRNA. a. Diagram of ex-
pression vector between SP6 transcription initiation site and SnaB1 restriction enzyme site. b. Denaturing agarose gel showing in vitro transcribed 
eGFP and GPC-3 mRNA. c. eGFP expression in monocyte-derived DC as determined by flow cytometry, 20 hours after mock transfection (filled area) 
or transfection with 20 μg eGFP mRNA (open area), when 64% of DC were positive for eGFP. d. GPC-3 expression in matured, monocyte-derived DC 
as determined by flow cytometry after staining with anti-GPC-3 antibody; left panel shows cell surface expression of GPC-3, 20 hours after mock trans-
fection or transfection with 20 μg GPC-3 mRNA, staining with isotype control antibody is shown for comparison; right panel shows intracellular expres-
sion after DC were permeabilised by drop-wise addition of the cells to ice cold 70% ethanol, 20 hours after mock transfection (thick line) or transfection 
with 20 μg GPC-3 mRNA (pale line), staining with isotype control antibody is shown for comparison (filled area).O'Beirne et al. Journal of Experimental & Clinical Cancer Research 2010, 29:48
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a s s e s s e d  w i t h  m e d i u m  a l o n e .  P e r c e n t a g e  s p e c i f i c  l y s i s
was calculated as (Experimental release - spontaneous
release)/(Maximum release - spontaneous release) × 100.
All determinations were made in triplicate.
Statistical analysis
All statistical analysis was performed using the Statistical
Program for Social Sciences (SPSS 14.0 for Windows;
SPSS Inc., Chicago, Illinois, USA), using the Mann-Whit-
ney test for unpaired and the Wilcoxon Signed Ranks test
for paired data. A difference between two variables was
considered significant when the two-tailed P value was <
0.05.
Results
Expression of transgenes in monocyte-derived dendritic 
cells following electroporation of mRNA
The yield of each SP6 mMessage Machine reaction was
around 20 μg of capped mRNA from 1 μg of linear DNA
template. Transcripts were extracted using RNAeasy col-
umns and the quality of the mRNA confirmed by dena-
turing agarose gel electrophoresis (Figure 1b).
Electroporation of 20 μg eGFP mRNA into monocyte-
derived DC resulted in 64% of DC expressing eGFP at 20
hours after transfection, as assessed by FACS analysis
(Figure 1c). Monocyte-derived DC transfected with 20 μg
GPC-3 mRNA and matured with LPS were stained with
anti GPC-3 antibody (1 μg/ml) and analyzed by flow
cytometry but cell surface expression of GPC-3 could not
be detected (Figure 1d left panel) until DC were permea-
bilised, by drop-wise addition of the cells to ice cold 70%
ethanol (Figure 1d right panel). These findings demon-
strate that transfection of DC with the synthetic mRNA
resulted in high levels of expression of GPC-3 or the con-
trol protein, eGFP.
T cells generated by DC transfected with GPC-3 mRNA are 
functional in vitro
GPC-3 mRNA transfected DC but not mock transfected
DC induced proliferation of autologous T cells (Figure
2a), indicating that T cells reacting to GPC-3 epitopes are
represented in the peripheral T cell repertoire. ELISPOT
assay for interferon-gamma production found that DC
expressing GPC-3 generated significantly more T cells
producing interferon-gamma than mock transfected DC
(53 ± 15 versus 4 ± 3 spots per well, respectively; p < 0.01)
(Figure 2b). These data demonstrate that monocyte-
derived DC transfected with GPC-3 mRNA and matured
with LPS were able to process and present GPC-3 derived
epitopes, resulting in the proliferation of autologous T
cells, which were functional as assessed by interferon-
gamma production.
Assessment of binding affinity of GPC-3 peptides to HLA-
A2
Among the 6 GPC-3 peptides tested, peptides 1, 2, 4 and
5 (GPC-3 229-237, 522-530, 186-194 and 222-230,
respectively) showed significant binding affinities,
whereas peptides 3 and 6 (GPC-3 299-307 and 169-177,
respectively) did not show significant binding under the
conditions used in these experiments (Figure 3). How-
ever, none of the GPC-3 peptides exhibited very strong
binding to HLA-A2, as all demonstrated weaker binding
than the "immunodominant" AFP peptide (GVALQT-
MKQ).
Induction of functional T cells in vitro by GPC-3 peptide-
loaded DC
Since the binding of a peptide to MHC class I molecules
does not necessarily mean that the epitope will be able to
induce MHC-restricted CTL, we examined whether
these peptides could generate peptide-specific T cells
from normal subjects. Peptide 2 GPC-3522-530 FLAEL-
AYDL, peptide 4 GPC-3186-194 GLPDSALDI, and peptide
5 GPC-3222-230 SLQVTRIFL were presented by HLA-A2,
inducing T cell proliferation, as assessed by thymidine
incorporation, in all donors to a level similar to that
induced by DC loaded with the "immunodominant" AFP
peptide (Figure 4a). Although, peptide 1 had shown high
affinity binding to HLA-A2, only 1 out of the 3 subjects
had highly reactive T cell proliferation to this epitope. DC
loaded with peptides 3 and 6 were unable to stimulate
autologous T cell responses in 2 subjects and induced
only low level T cell proliferation in the other. These data
showed a good correlation between the peptide's
observed binding affinity for HLA-A2 and the ability of
DC loaded with peptide to induce autologous T cell pro-
liferation.
T cell function was assessed by their ability to lyse chro-
mium-labelled HepG2 cells (HLA-A2+, GPC-3+) as tar-
gets. CD8+ enriched T cells were stimulated twice by
autologous, γ-irradiated, peptide-pulsed, matured DC. T
cells harvested after two rounds of stimulation with DC
pulsed with GPC-3 peptides 2 or 5, or the "immunodomi-
nant" AFP peptide efficiently lysed HepG2 cell targets
(Figure 4b). Notably, although T cells were generated by
DC loaded with GPC-3 peptide 4, GPC-3186-194 GLPD-
SALDI, they were not significantly better at lysing targets
than T cells stimulated by control, unpulsed DC. This
finding suggests that either CTL reacting against this
epitope (GPC3186-194  GLPDSALDI) were ineffective or
this epitope was not generated by the proteasome in
HepG2 cells and hence not presented in association with
HLA-A2 at the cell surface. There were insufficient CD8+
T cells generated against epitope GPC3186-194  GLPD-O'Beirne et al. Journal of Experimental & Clinical Cancer Research 2010, 29:48
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SALDI to test whether they could lyse targets pulsed with
GLPDSALDI peptide.
Processing of HLA-A2-restricted GPC-3 epitopes by mRNA 
transfected DC
On the basis of the above results, GPC-3 peptide epitopes
2 and 5 were selected for further investigation to establish
whether these epitopes are generated and presented in
association with HLA-A2 by DC transfected with GPC-3
mRNA. T cell pools were generated by stimulation of
PBMC with autologous, irradiated, matured DC pulsed
with 1 μM GPC-3 or irrelevant control peptides, or with
autologous, irradiated, matured DC transfected with
GPC-3 mRNA or eGFP mRNA, as control. A second
round of stimulation was performed with autologous,
irradiated, matured DC pulsed with 1 μM GPC-3 or irrel-
evant control peptides. DC pulsed with peptide 2 (GPC-
3522-530 FLAELAYDL) not only induced proliferation in T
cells previously expanded by DC pulsed with the same
peptide, as expected, but also in T cells previously
expanded by DC transfected with GPC-3 mRNA but not
eGFP mRNA, indicating that the GPC-3 mRNA trans-
fected DC expressed HLA-A2/FLAELAYDL complex on
the cell surface and were able to expand viable CD8+ T
cell precursors. Hence, the GPC-3522-530  FLAELAYDL
epitope is generated by the MHC class I processing path-
way in DC. In contrast, although DC pulsed with peptide
5 (GPC-3222-230 SLQVTRIFL) induced proliferation in T
cells previously expanded by DC pulsed with the same
peptide, they failed to stimulate proliferation of T cells
previously expanded by DC transfected with either GPC-
3 mRNA or eGFP mRNA, suggesting that the epitope,
SLQVTRIFL, was not processed for presentation in asso-
ciation with HLA-A2 in the GPC-3 mRNA transfected
DC (Figure 5).
Discussion
In this study, we show that T cells reacting to GPC-3
epitopes are represented in the peripheral T cell reper-
toire of normal human subjects. Despite being exposed to
this oncofoetal protein during embryonic development
not all GPC-3-specific T cells were deleted during the
ontogeny of the immune system. The data clearly demon-
strate that monocyte-derived DC electroporated with
GPC-3 mRNA efficiently presented GPC-3 epitopes to
autologous T cells and generated functional GPC-3-reac-
tive T cells in vitro as shown by production of interferon-
gamma.
Figure 2 T cells generated by DC transfected with GPC-3 mRNA are functional in vitro. PBMC were depleted of HLA class II positive cells and co-
cultured with autologous, γ-irradiated, LPS matured DC in serum-free X-Vivo medium supplemented on days 1, 3 and 7 of culture with IL-2 (20 U/ml) 
and IL-7 (10 ng/ml). After 7 days, T cells were re-stimulated with the same DC for a further 5 days. a. T cell proliferation (1 × 105/well) was measured 
by 3H-thymidine incorporation, T cells were cultured alone, with DC (1 × 104/well) transfected with 20 μg GPC-3 mRNA, or mock transfected DC. b. 
ELISPOT assay for interferon-γ production was performed on T cells (1 × 105/well) stimulated by DC transfected with 20 μg GPC-3 mRNA or mock trans-
fected DC.O'Beirne et al. Journal of Experimental & Clinical Cancer Research 2010, 29:48
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Several studies have confirmed the very high sensitivity
and specificity of GPC-3 over-expression for differentiat-
ing HCC from non-malignant liver tissue [9,24-28].
Nonetheless, a recent study reported GPC-3 immunore-
activity in inflammatory liver biopsies from patients with
chronic hepatitis C [29] and a further study reported the
up-regulation of GPC-3 in monocyte-derived DC after
maturation [30]. The discovery of GPC-3 protein in non-
malignant adult tissue, whether inflamed liver or mature
DC, challenges the hypothesis that GPC-3 is a potential
target TAA for HCC immunotherapy because of the
spectre that the generation of GPC-3-reactive T cells
would induce auto-immune disease. Reassuringly, in the
present study, flow cytometry analysis after staining per-
meabilised, monocyte-derived DC with a labelled anti-
GPC-3 monoclonal antibody detected intracellular stain-
ing of GPC-3 only in matured, GPC-3 mRNA transfected
DC and not in matured, control DC; we did not detect
surface expression of GPC-3 in any DC. The reason for
the discrepancy between our findings and those of
Wegrowski et al [30] needs further investigation, but they
utilised RT-PCR to detect GPC-3 mRNA and Western
blot to detect the protein both of which are more sensi-
tive assays than the flow cytometry analysis used in the
present study. However, it should be emphasised that
there was no evidence of stimulation of GPC-3-specific T
cells by control DC in the present study. Murine studies
have also provided reassuring data, as DC modified to
express GPC-3 were shown to elicit effective antitumor
immunity with no evidence of induction of autoimmune
injury to liver or other organs [12,13,31].
Mature GPC-3 is modified post-translation into a hepa-
ran sulphate proteoglycan [8]. Although the addition of
the carbohydrate moiety could potentially mask some
and generate other novel B-cell epitopes, it will not inter-
fere with the presentation of MHC class I-restricted
epitopes to CD8+ T cells. Previously, it was believed that
mature cellular proteins were the main source of anti-
genic peptides but it is now known that MHC class I pep-
tides originate predominantly from newly synthesised
proteins [32], around 30% of which are immediately poly-
ubiquitinylated and subsequently cleaved by the protea-
some. The resulting peptides of 8-11 residues in length
are then transported into the endoplasmic reticulum, by
the transporter associated with antigen presentation
(TAP) complex, where they are assembled with MHC
class I molecules [33]. Given that newly synthesised GPC-
3 protein will be processed by the proteasome before
post-translational modification, the carbohydrate moiety
will not affect the presentation of peptide epitopes by
Figure 3 Binding affinity of GPC-3 peptides to HLA-A2. T2 cells were plated into 96-well U-bottomed plates at 1 × 105 cells per well in 200 μL X-
Vivo (Biowhittaker) and cultured overnight at 18°C to increase cell surface HLA-A2 expression. a. 3 hours after pulsing with increasing concentration 
of GPC-3 peptides, positive control (AFP) peptide or negative control (random) peptide plus 5 nM β2 microglobulin and incubation at 37°C, T2 cells 
were stained with a FITC-conjugated HLA-A2 specific antibody and examined by flow cytometry; b. T2 cells were stained with a FITC-conjugated HLA-
A2 specific antibody and examined by flow cytometry at time points after the cells had been incubated for 3 hours at 37°C with 100 μM peptide, 5 
nM β2 microglobulin and 5 μg/ml Brefeldin A. The data shown are representative of three independent experiments.O'Beirne et al. Journal of Experimental & Clinical Cancer Research 2010, 29:48
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MHC class I molecules. CD8+ T cell receptors recognise
only GPC-3 epitopes expressed in association with MHC
class I molecules rather than the intact mature protein at
the cell surface.
A second aim of this study was to identify HLA-A2-
restricted epitopes derived from GPC-3. When we ana-
lyzed the amino acid sequence of human GPC-3, 6
sequences were identified that were predicted both to
bind to HLA-A2 and to be processed by the proteasome.
W e used flow cytometry analysis of T2 cells, which are
TAP deficient, to measure the half-life of peptide binding
to HLA-A2 and identified 4 peptides with prolonged,
high affinity binding for HLA-A2. Of these, GPC-3522-530
FLAELAYDL, fulfilled our criteria as a naturally pro-
cessed, HLA-A2-restricted CTL epitope because: i) it was
generated by the MHC class I processing pathway in DC
transfected with GPC-3 mRNA, and ii) HLA-A2 positive,
monocyte-derived DC loaded with the peptide stimu-
lated proliferation in autologous T cells and generated
CTL that lysed HLA-A2 and GPC-3 positive tumour
cells. One of the peptides GPC-3169-177 ELFDSLFPV pre-
dicted to have strong binding to HLA-A2 was found to
rapidly dissociate from HLA-A2 in the present study and
DC loaded with this peptide did not stimulate autologous
T cells in HLA-A2 positive subjects, a finding confirmed
by Nishimura and colleagues who found that DC loaded
with GPC-3169-177  E L F D S L F P V  w e r e  u n a b l e  t o  i n d u c e
CTL or T cells producing interferon-gamma [34].
Previously, Komori et al used HLA-A2.1 transgenic
m i c e  t o  i d e n t i f y  H L A - A 2  ( A*0201)-restricted GPC-3
epitopes but found no evidence that CTL were generated
against GPC-3522-530 FLAELAYDL in animals immunized
with DC pulsed with a mixture of peptides because, after
Figure 4 Induction of functional T cells in vitro by GPC-3 peptide-
loaded DC. a. PBMC (1 × 105/well), depleted of HLA class II positive 
cells, from 3 healthy HLA-A2 positive subjects were stimulated twice 
with autologous, monocyte-derived DC (1 × 104/well), which had been 
pulsed with 1 μM peptides for 3 hours, matured with LPS and γ-irradi-
ated, in serum-free X-Vivo medium supplemented with IL-2 (20 U/ml) 
and IL-7 (10 ng/ml). T cell proliferation was measured by 3H-thymidine 
incorporation, Stimulation Index is ratio of T cell proliferation due to 
peptide-pulsed DC ÷ control DC. b. CD8+ enriched T cells were stimu-
lated twice by autologous, γ-irradiated, peptide-pulsed, matured DC. 
The ability of these CD8+ T cells to lyse HepG2 cells was assessed by 
chromium release assay. Target cells (HepG2) were labelled with 200 
μCi Na2
51CrO4 and plated (5 × 103 cells/well) in round-bottomed 96 
well plates. Effector cells were added at graded effector/target ratios 
and after 4 hours incubation at 37°C, 50 μl of the culture supernatant 
was harvested and radioactivity counted in a scintillation counter. 
Spontaneous release was <15% in all assays. Error bars reflect standard 
error of mean of 3 experiments.
Figure 5 Processing of HLA-A2-restricted GPC-3 epitopes by 
mRNA transfected DC. T cell pools were expanded firstly by a round 
of stimulation with autologous, irradiated, matured DC pulsed with 1 
μM GPC-3 or irrelevant control peptides, or DC transfected with either 
GPC-3 mRNA or eGFP mRNA as control, followed by a second round of 
stimulation with autologous, irradiated, matured DC pulsed with 1 μM 
GPC-3 or irrelevant control peptides. T cell proliferation was assessed 
by thymidine incorporation, at a stimulator to responder ratio of 1:10. 
* p < 0.05 and ** p < 0.01 compared to T cells stimulated in the first 
round by eGFP mRNA transfected DC; error bars reflect standard error 
of mean of 3 experiments.O'Beirne et al. Journal of Experimental & Clinical Cancer Research 2010, 29:48
http://www.jeccr.com/content/29/1/48
Page 9 of 11
spleen cell harvest, only CD4- T cells stimulated in vitro
with the peptide GPC-3144-152  FVGEFFTDV produced
high levels of interferon-γ[31]. These findings suggest
that the epitope GPC-3144-152 might be immunodominant
in this system or, alternatively, CTL reactive to GPC-3522-
530 may not have been generated in HLA-A2.1 transgenic
mice due to differences in the T cell repertoire between
mice and humans, resulting in some HLA-A2-restricted
epitopes being recognized only by human T cells. Non-
dominant epitopes, although having a weaker affinity to
MHC, can still induce reactive CTL with cytotoxic activ-
ity and thus be applicable for immunotherapy [35].
Indeed, T cells responding to such epitopes are often bet-
ter represented in the peripheral T cell repertoire because
those responding to self-epitopes with strong MHC bind-
ing are more likely to be deleted in the thymus during the
ontogeny of the immune system [36].
Three additional GPC-3 peptides found to have high
affinity binding for HLA-A2 in the present study are
thought to be less suitable for further clinical investiga-
tion because either T cells from the peripheral T cell rep-
ertoire were poorly reactive (peptide 1, GPC-3229-237
FLQALNLGI), or the epitopes were not generated by the
MHC class I processing pathways in the HCC cell line
used as the target cell for the CTL assay (peptide 4, GPC-
3186-194 GLPDSALDI) or in the DC (peptide 5, GPC-3222-
230  SLQVTRIFL). Interestingly, CTL generated by DC
loaded with peptide 5 effectively lysed HepG2 cells, indi-
cating that it was expressed in association with HLA-A2
on the surface of the tumour cells, possibly reflecting dif-
ferences in the cleavage of the GPC-3 polypeptide by the
constitutive proteasome in the tumour cell line and the
immunoproteasome in DC [37]. Variable numbers of
CD8+ precursor T cells in the small number of donors
tested or less efficient presentation of peptide 5 by the
DC, relative to peptide 2, seem unlikely explanations for
the findings as two rounds of stimulation by DC loaded
with peptide 5 induced high levels of T cell proliferation
and functional CTL in all subjects tested.
GPC-3 appears to be an eminently suitable target mole-
cule for HCC immunotherapy because it is a foetal pro-
tein [8] that is expressed early in the development of HCC
[38] and has been implicated directly in tumour progres-
sion. Membrane bound GPC-3 has been postulated to
stimulate the growth of HCC by both facilitating the
interaction of Wnt with its signalling receptors [39] and
enhancing fibroblast growth factor 2 signalling [40]. Acti-
vation of the canonical Wnt pathway is a frequent event
associated with the malignant transformation of hepato-
cytes [41], leading to a rise in β-catenin in the nucleus,
which in turn regulates transcription factors controlling
hepatoma cell growth [42,43]. Knockdown of GPC-3 was
found to attenuate fibroblast growth factor 2 binding, a
mitogen that promotes HCC cell proliferation and migra-
tion by activating downstream protein kinase pathways
[40]. In addition, GPC-3 expression stimulates the
recruitment of macrophages into HCC, especially mac-
rophages with a phenotype promoting tumour progres-
sion and metastasis [44]. Therefore, although the
generation of escape mutants due to loss of expression or
mutation of a TAA could lead to the failure of immuno-
t h e r a p y ,  l o s s  o f  G PC - 3  e x p r e s s i o n  b y  H C C ,  u n d e r  t h e
selective pressure of attack by antigen specific T cells, is
likely to be mitigated by diminished tumour growth and
invasiveness.
Conclusions
The findings of this study confirm previous reports that
electroporation of mRNA encoding a TAA is an efficient
method to load human monocyte-derived DC with anti-
gen [45]. GPC-3 mRNA transfected DC generated GPC-
3-reactive T cells that were functional, as shown by inter-
feron-gamma production.
This study also identified a peptide, GPC-3522-530 FLAE-
LAYDL, that fulfilled criteria as a naturally processed,
HLA-A2-restricted CTL epitope. We anticipate that this
epitope and the HLA-A2-restricted GPC-3 epitope,
GPC3144-152 FVGEFFTDV, identified by a previous HLA-
A2 transgenic mouse study [31], can be utilized to moni-
tor CTL responses in patients undergoing immunother-
apy studies of GPC-3-loaded DC. These studies will
determine the probability of successful generation of
HLA-A2-restricted CTL reactive to these epitopes in
patients with malignancy.
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